CRISPR Therapeutics AG
NASDAQ:CRSP 9:37:18 AM EDT
| Market Cap (Intraday) | 4.73B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $58.07 |
| 50-Day MA | $72.18 |
| 200-Day MA | $59.50 |
CRISPR Therapeutics AG Stock, NASDAQ:CRSP
Baarerstrasse 14, Zug, Zug 6300
Switzerland
Phone: +41.41.561.32.77
Number of Employees: 407
Description
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.